MONETA, CLAUDIA
MONETA, CLAUDIA
Universita' degli Studi di MILANO
Will the autofluorescence take over inadvertent parathyroidectomy?Results from a multicentre cohort study
2025 D. Barbieri, P. Indelicato, S. DE LEO, C. Moneta, S. Coccia, G. Gazzano, L. Giordano, F. LIRA LUCE, D. Canta, L. Fugazzola, M. Bussi, G. Dionigi, M. Trevisan
Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
2024 C. Colombo, D. Ceruti, M. Succi, S. De Leo, M. Trevisan, C. Moneta, L. Fugazzola
Thyroid cancer and endocrine disruptive chemicals: a case–control study on per-fluoroalkyl substances and other persistent organic pollutants
2024 V. Cirello, M. Lugaresi, C. Moneta, P. Dufour, A. Manzo, E. Carbone, C. Colombo, L. Fugazzola, C. Charlier, C. Pirard
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
2023 S. De Leo, M. Trevisan, C. Colombo, C. Moneta, N. Giancola, L. Fugazzola
Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer
2023 S. De Leo, M. Trevisan, G.V. Re Sartò, C. Moneta, M. Pirovano, C. Colombo, L. Cosmai, L. Fugazzola
Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
2023 S. De Leo, M. Trevisan, C. Moneta, C. Colombo
Management of hypertension during Lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
2023 C. Colombo, D. Ceruti, S. DE LEO, G. Bilo, M. Trevisan, N. Giancola, C. Moneta, G. Parati, L. Persani, L. Fugazzola
Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
2022 M. Trevisan, C. Colombo, N. Giancola, C. Moneta, G. Dionigi, L. Fugazzola, S. De Leo
Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review
2021 C. Colombo, S. De Leo, M. Di Stefano, M. Trevisan, C. Moneta, L. Vicentini, L. Fugazzola